
A-674563 2HCl(552325-73-2(fb-2hcl))
CAS No. ——
A-674563 2HCl(552325-73-2(fb-2hcl)) ( —— )
产品货号. M22765 CAS No. ——
A-674563 是一种 Akt1 抑制剂,Ki 为 11 nM,对 PKA 效力适中,对 Akt1 的选择性比 PKC 高 30 倍以上。A-674563 可减少细胞中 Akt 下游靶标的磷酸化,并在体外减缓肿瘤细胞的增殖(EC50: 0.4 μM)[1]。 A563 (0-10 μM) 显着降低 STS 细胞中 GSK3 和 MDM2 的磷酸化。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥1497 | 有现货 |
![]() ![]() |
10MG | ¥2499 | 有现货 |
![]() ![]() |
25MG | ¥3448 | 有现货 |
![]() ![]() |
50MG | ¥5280 | 有现货 |
![]() ![]() |
100MG | 获取报价 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称A-674563 2HCl(552325-73-2(fb-2hcl))
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述A-674563 是一种 Akt1 抑制剂,Ki 为 11 nM,对 PKA 效力适中,对 Akt1 的选择性比 PKC 高 30 倍以上。A-674563 可减少细胞中 Akt 下游靶标的磷酸化,并在体外减缓肿瘤细胞的增殖(EC50: 0.4 μM)[1]。 A563 (0-10 μM) 显着降低 STS 细胞中 GSK3 和 MDM2 的磷酸化。
-
产品描述A-674563 is an Akt1 inhibitor with Ki of 11 nM, modest potent to PKA and >30-fold selective for Akt1 over PKC.A-674563 reduces phosphorylation of Akt downstream targets in cells and slows proliferation of tumor cells in vitro (EC50: 0.4 μM). A563 (0-10 μM) markedly decreases GSK3 and MDM2 phosphorylation in STS cells. A563 shows inhibitory effect on all STS cell lines, with IC50 values at 48 hours ranging from 0.22 μM to 0.35 μM. A563 induces G2 cell cycle arrest and apoptosis in STS cells. A563 (1 μM/12 hr) upregulates the expression of GADD45A independent of p53. A-674563 (10-1000 nM) is anti-proliferative and cytotoxic in cultured human melanoma cells, induces melanoma cell apoptotic death, inhibited by caspase inhibitors, and inhibits melanoma cells via Akt-dependent and -independent mechanisms. A-674563 is cytotoxic and anti-proliferative when added to U937 and AmL progenitor cells activate caspase-3/9 and apoptosis in U937 and AmL progenitor cells and manipulate other signalings in AmL cells whiling blocking Akt.In the PC-3 prostate cancer xenograft model, A-674563 (40 mg/kg/d, p.o.) has no marked monotherapy activity, but the efficacy of the combination therapy (A-674563+paclitaxel) is significantly improved. In an oral glucose tolerance test, A-674563 (20, 100 mg/kg) can increase plasma insulin. A563 (20 mg/kg/bid; p.o.) exhibits slow tumor growth and a significant difference in tumor volume without significant weight loss of mice. A563-treated tumors express increased levels of GADD45α and decreased levels of PCNA (a nuclear marker for proliferation). Additionally, TUNEL assay staining levels (marker for apoptosis) increase in the A563-treated specimens. A-674563 (25, 100 mg/kg, lavage daily) effectively inhibits A375 xenograft growth in mice. A-674563 (15, 40 mg/kg) injection inhibits U937 xenograft in vivo growth and improves mice survival.
-
体外实验——
-
体内实验——
-
同义词——
-
通路Cytoskeleton/Cell Adhesion Molecules
-
靶点Akt
-
受体Akt1|CDK2|PKA|ERK2|PKCδ
-
研究领域——
-
适应症——
化学信息
-
CAS Number——
-
分子量431.36
-
分子式C22H24Cl2N4O
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESCl.Cl.Cc1n[nH]c2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Luo Y, Shoemaker A R, Liu X, et al. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo.[J]. Molecular Cancer Therapeutics, 2005, 4(6):977.